Skip to main content
SpringerLink
Log in

Clinical Management

  • Chapter
The Paris System for Reporting Urinary Cytology

Abstract

Urine cytology is utilized in various clinical scenarios, including the evaluation of hematuria or voiding symptoms, the initial workup for a suspected urothelial malignancy, and for ongoing surveillance following treatment for urothelial cancer. The primary goal of the clinician evaluating these patients is to ensure that a potentially lethal urothelial malignancy is not missed. When combined with upper tract radiographic imaging and direct cystoscopic evaluation, urine cytology provides a powerful means to accomplish this goal.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urine markers for detection and surveillance of bladder cancer. Urol Oncol. 2014;32:222–9.

    Article  CAS  PubMed  Google Scholar 

  2. Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33:66. e25–31.

    Article  PubMed  Google Scholar 

  3. Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188:2473–81.

    Article  PubMed  Google Scholar 

  4. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–30.

    Article  PubMed  Google Scholar 

  5. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–63.

    Article  PubMed  Google Scholar 

  6. Mitra AP, Alemozaffar M, Harris BN, Schuckman AK, Skinner EC, Daneshmand S. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Urology. 2014;84:1420–6.

    Article  PubMed  Google Scholar 

  7. Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012;188:2046–54.

    Article  PubMed  Google Scholar 

  8. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004;172:1342–7.

    Article  PubMed  Google Scholar 

  9. Sanderson KM, Cai J, Miranda G, Skinner DG, Stein JP. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol. 2007;177:2088–94.

    Article  PubMed  Google Scholar 

  10. Stein JP, Penson DF, Wu SD, Skinner DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol. 2007;178:756–60.

    Article  PubMed  Google Scholar 

  11. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, et al. ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2013;63:4–15.

    Article  PubMed  Google Scholar 

  12. Bubendorf L, Piaton E. UroVysion(R) multiprobe FISH in the triage of equivocal urinary cytology cases. Ann Pathol. 2012;32(6):e52–6. 438–43.

    Article  PubMed  Google Scholar 

  13. Yoder BJ, Skacel M, Hedgepeth R, Babineau DF, Ulchaker JC, Liou LS, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007;127:295–301.

    Article  PubMed  Google Scholar 

  14. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101–5.

    Article  CAS  PubMed  Google Scholar 

  15. Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S, et al. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67:876–88.

    Article  PubMed  Google Scholar 

  16. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11:589–96.

    CAS  PubMed  Google Scholar 

  17. Gayed BA, Seideman C, Lotan Y. Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol. 2013;190:1181–6.

    Article  CAS  PubMed  Google Scholar 

  18. Herr HW. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. Eur Urol. 2015;67:605–8.

    Article  PubMed  Google Scholar 

  19. Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015;121:169–78.

    Article  PubMed  Google Scholar 

  20. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184:1907–13.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66:863–71.

    Article  PubMed  Google Scholar 

  22. Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;192:305–15.

    Article  PubMed  Google Scholar 

  23. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am. 2015;29:237–52.

    Article  PubMed  Google Scholar 

  24. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: The University of Southern California experience. J Urol. 2005;174:93–6.

    Article  PubMed  Google Scholar 

  25. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson Cancer experience. J Urol. 2004;172:481–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Loyola University Health Systems, Loyola University, 2160 S. First Avenue, Fahey Center, Room 261, Chicago, IL, 60153, USA

    Marcus L. Quek M.D.

  2. Department of Urology, The Johns Hopkins Hospital, The Johns Hopkins University, Baltimore, MD, USA

    Trinity J. Bivalacqua M.D., Ph.D.

  3. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Ashish M. Kamat M.D.

  4. Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA

    Mark P. Schoenberg M.D.

Authors
  1. Marcus L. Quek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trinity J. Bivalacqua M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ashish M. Kamat M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mark P. Schoenberg M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus L. Quek M.D. .

Editor information

Editors and Affiliations

  1. The Johns Hopkins Hospital, The Johns Hopkins University, Baltimore, Maryland, USA

    Dorothy L. Rosenthal

  2. Department of Pathology, Loyola University Medical Center Department of Pathology, MAYWOOD, Illinois, USA

    Eva M. Wojcik

  3. Department of Pathology and Laboratory M, University of Wisconsin School of Medine Department of Pathology and Laboratory M, MADISON, Wisconsin, USA

    Daniel F.I. Kurtycz

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Quek, M.L., Bivalacqua, T.J., Kamat, A.M., Schoenberg, M.P. (2016). Clinical Management. In: Rosenthal, D., Wojcik, E., Kurtycz, D. (eds) The Paris System for Reporting Urinary Cytology. Springer, Cham. https://doi.org/10.1007/978-3-319-22864-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22864-8_11

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22863-1

  • Online ISBN: 978-3-319-22864-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation